Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619190 · ClinicalTrials.gov registry record · Phase 2
Study of Aripiprazole to Treat Children and Adolescents With Autism
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00619190 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants.
The verdict
NCT00619190, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this open label study in children and adolescents is to examine the acute and long-term effects of aripiprazole on problem behaviors associated with autism spectrum disorders and development in areas which appear to be affected by autism spectrum disorders.
Interventions
- DRUG aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619190
The ClinicalTrials.gov registry entry for NCT00619190 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aripiprazole is the first listed.
NCT00619190 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619190 about?
NCT00619190 is a clinical study titled "Study of Aripiprazole to Treat Children and Adolescents With Autism". The purpose of this open label study in children and adolescents is to examine the acute and long-term effects of aripiprazole on problem behaviors associated with autism spectrum disorders and development in areas which appear to be affected by autism spectrum disorders.
What is the current status of trial NCT00619190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00619190?
The interventions under investigation include: aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00619190?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.